Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes
© Warnat et al; licensee BioMed Central Ltd. 2007
Received: 21 December 2006
Accepted: 25 May 2007
Published: 25 May 2007
Neuroblastoma patients show heterogeneous clinical courses ranging from life-threatening progression to spontaneous regression. Recently, gene expression profiles of neuroblastoma tumours were associated with clinically different phenotypes. However, such data is still rare for important patient subgroups, such as patients with MYCN non-amplified advanced stage disease. Prediction of the individual course of disease and optimal therapy selection in this cohort is challenging. Additional research effort is needed to describe the patterns of gene expression in this cohort and to identify reliable prognostic markers for this subset of patients.
We combined gene expression data from two studies in a meta-analysis in order to investigate differences in gene expression of advanced stage (3 or 4) tumours without MYCN amplification that show contrasting outcomes (alive or dead) at five years after initial diagnosis. In addition, a predictive model for outcome was generated. Gene expression profiles from 66 patients were included from two studies using different microarray platforms.
In the combined data set, 72 genes were identified as differentially expressed by meta-analysis at a false discovery rate (FDR) of 8.33%. Meta-analysis detected 34 differentially expressed genes that were not found as significant in either single study. Outcome prediction based on data of both studies resulted in a predictive accuracy of 77%. Moreover, the genes that were differentially expressed in subgroups of advanced stage patients without MYCN amplification accurately separated MYCN amplified tumours from low stage tumours without MYCN amplification.
Our findings support the hypothesis that neuroblastoma consists of two biologically distinct subgroups that differ by characteristic gene expression patterns, which are associated with divergent clinical outcome.
Neuroblastoma is a malignant tumour of the sympathetic nervous system. Next to brain tumours, it is the most common solid tumour in children, with 7.5 cases per 100,000 infants . The hallmark of this tumour is its heterogeneous clinical behaviour, ranging from life-threatening tumour progression to spontaneous regression or differentiation to benign ganglioneuroma. To discriminate these contrasting patterns of clinical behaviour, several molecular and cytogenetic features, such as amplification of the MYCN oncogene or deletion of chromosomal material from 1p or 11q are currently used in clinical trials [1, 2]. However, the course of intermediate risk patients with MYCN non-amplified advanced stage disease is still hard to predict by these markers, and optimal therapy selection in this cohort remains challenging. Thus, current neuroblastoma trials may stratify these advanced stage MYCN non-amplified patients to either the low-, the intermediate- or the high-risk group leading to highly differing treatment approaches . Therefore, additional research effort is needed to identify reliable prognostic markers for these subsets of patients .
To this end, recent studies applied gene expression profiling to investigate divergent clinical neuroblastoma phenotypes [5–8]. These studies have shown that it is possible to discriminate subtypes of neuroblastomas of diverse molecular and clinical phenotype by their gene expression profiles. However, gene expression data for the important subgroup of MYCN non-amplified neuroblastoma patients of advanced stage disease (International Neuroblastoma Staging System, INSS Stage 3 or 4,) is still rare, leading to a high risk of false positive and false negative findings .
In this study, we combined gene-expression data from two different studies generated by different platforms, since a combined analysis yields more information than each individual study [10, 11]. Although microarray data generated by different platforms are not directly comparable, they can be combined in an integrative analysis, if appropriate methods are carefully chosen . We focused on MYCN non-amplified tumours with advanced INSS stage 3 or 4. We searched for differences in gene expression between patients with contrasting outcomes (alive or dead) at five years after initial diagnosis. Differentially expressed genes were identified and described based on data of the two largest neuroblastoma gene expression studies to date [7, 8]. In addition, a predictive model (classifier) for patient outcome was generated and assessed.
Gene Expression Data
Microarray data by Ohira et al.  were downloaded from the NCBI GEO  database (accession number GSE2283), and microarray data by Oberthuer et al.  were downloaded from the EBI ArrayExpress  database (accession number E-TABM-38). For both data sets normalized expression data were used as published.
The probes of the different microarray platforms were mapped by a perfect match of their sequences. If an oligonucleotide probe of the platform used by Oberthuer et al. had a sequence that could be matched to a part of the GenBank mRNA sequence corresponding to a cDNA clone probe of the platform used by Ohira et al., both probes were considered as representing the same transcript. For genes represented by several probes on a platform the median expression value of all corresponding probes was used.
Gene expression profiles of patients were selected from both studies according to the following criteria: MYCN non-amplified tumors with advanced INSS stage (3 or 4) with either a minimum follow-up time of five years after diagnosis or with fatal outcome of disease. All patients were grouped according to their outcome status (alive vs. dead) five years after initial diagnosis. In addition, we randomly selected 40 other patients from both studies (MYCN amplified stage 3 or 4 tumours, ten of each study; MYCN non amplified tumours with stages 1, 2 or 4S, ten of each study). According to their clinical characteristics, these patients have either a highly aggressive neuroblastoma tumour or a tumour with very good prognosis. We used the microarray data of these tumors to study the expression of the genes found to be differentially expressed in our meta-analysis of intermediate risk neuroblastomas in patients with either distinct favourable or unfavourable course of disease.
Identification of significant genes
To detect significant differential expression of a gene between the two outcome patient groups across studies, we applied a meta-analysis approach as described by Choi et al. . The Bioconductor  software package GeneMeta was used to perform these calculations.
Moreover, to explore the biological aspects of the significant genes, we analysed the associated Gene Ontology (GO)  terms using the GOstat software , which generates statistics of which annotations are overrepresented in a given list of genes.
A predictive model for the patient outcome status (alive vs. dead) five years after diagnosis was generated using the method of nearest shrunken centroids classification .
Using only the data of genes represented on both microarray platforms (n = 1,271), we applied a methodology evaluated by Warnat et al. , namely the median rank scores (MRS), to derive numerically comparable quantities from the expression values of both platforms used in the different studies. In total, 36 patients were selected from both studies as a training set to generate a predictive model of patient outcome (Additional File 1). The remaining 30 patients were used as an independent test set. In addition, samples of the independent test set were classified according to the clinical markers age at diagnosis and INSS stage.
Supplementary information is available at the website of BMC Cancer.
Gene Expression Data
We focused on data of the two biggest current neuroblastoma gene-expression studies from Ohira et al.  and Oberthuer et al. . These studies analysed a total of 136 (Ohira) and 251 patients (Oberthuer). Further neuroblastoma gene expression studies by Wei et al.  and Schramm et al.  comprised 18 and 4 patients that met the criteria of our cohort (patients with advanced stage disease without MYCN-amplification). However, based on mappings to the Unigene database, the number of UniGene clusters represented on each of the four microarray platforms used in the studies of Wei et al., Schramm et al., Ohira et al. and Oberthuer et al. only sums up to 362 UniGene clusters. In addition, the data of Wei et al. is not available in a public microarray data repository. Thus, we decided to use only data from the studies of Ohira et al. and Oberthuer et al.
Oberthuer et al.
Ohira et al.
Although risk stratification and treatment strategies of neuroblastoma are different for a small fraction of patients [ref.  and Additional File 1] between Japan and Germany, the resulting 5-years overall survival is comparable among the German and Japanese neuroblastoma risk groups, suggesting that the selected patient cohorts from both studies [7, 8] can be compared in a combined analysis as performed here.
Identification of significant genes
List of differentially expressed genes.
only found in M.A.
NADH dehydrogenase (ubiquinone) flavoprotein 1, 51 kDa
Tumor protein p53 (Li-Fraumeni syndrome)
Nucleophosmin (nucleolar phosphoprotein B23, numatrin)
Chromodomain helicase DNA binding protein 1-like
Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa)
Splicing factor 4
Ribosomal protein S13
E2F transcription factor 1
Nuclear protein UKp68
RuvB-like 1 (E. coli)
Chaperonin containing TCP1, subunit 5 (epsilon)
Chaperonin containing TCP1, subunit 3 (gamma)
DEAD (Asp-Glu-Ala-Asp) box polypeptide 49
Eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa
Kinesin family member C1
Hypothetical protein FLJ13910
APEX nuclease (multifunctional DNA repair enzyme) 1
Coatomer protein complex, subunit beta
Cell division cycle 25B
transmembrane emp24 domain trafficking protein 2
S-adenosylhomocysteine hydrolase-like 1
RAD23 homolog A (S. cerevisiae)
High-mobility group box 2
Tripartite motif-containing 28
Enolase 1, (alpha)
Mitochondrial ribosomal protein L3
MAP/microtubule affinity-regulating kinase 2
DEAD (Asp-Glu-Ala-Asp) box polypeptide 1
Kinesin family member 22
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein
Dual specificity phosphatase 16
Enhancer of zeste homolog 1 (Drosophila)
Neural cell adhesion molecule 1
Mitogen-activated protein kinase kinase 4
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu antigen D)
RNA binding motif, single stranded interacting protein
PX domain containing serine/threonine kinase
Exosome component 10
Neurotrophic tyrosine kinase, receptor, type 1
Dedicator of cytokinesis 4
DIX domain containing 1
RAB2, member RAS oncogene family
Forkhead box P1
G protein pathway suppressor 2
Myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax homolog, Drosophila)
Discs, large homolog 4 (Drosophila)
Vesicle-associated membrane protein 2 (synaptobrevin 2)
ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A
zinc finger protein 218
Receptor accessory protein 1
Cyclin-dependent kinase 5, regulatory subunit 1 (p35)
nuclear receptor coactivator 7
Chromosome 1 open reading frame 149
Myristoylated alanine-rich protein kinase C substrate
Calmodulin binding transcription activator 1
sodium channel, voltage-gated, type III, beta
Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1)
Epidermal growth factor receptor pathway substrate 15
Bruno-like 4, RNA binding protein (Drosophila)
Doublecortin and CaM kinase-like 1
ALS2 C-terminal like
Hypothetical protein LOC284244
Rap guanine nucleotide exchange factor (GEF) 6
Protein kinase (cAMP-dependent, catalytic) inhibitor beta
Hypothetical protein LOC116236
FYN oncogene related to SRC, FGR, YES
Clinical courses observed in non-amplified advanced stage patients with differing gene-expression patterns
In the data set of Oberthuer et al., seven patients that were alive five years after diagnosis were clustered together with those patients that had succumbed to disease (Fig. 1A). Three of them had experienced an event, two of them even had been treated with intensive salvage therapy, but all are currently in complete or incomplete remission. Opposed to that, three patients were documented to have experienced an event within the subset of patients that were clustered together as being alive five years after diagnosis. In all these patients, local tumour progression was diagnosed but either surgical intervention revealed maturation of the tissue or medium-dose chemotherapy resulted in event-free survival since then. Thus, a different quality of events was observed in those patients whose gene-expression profile resembles that of patients who succumbed to disease, as opposed to those events that were observed in patients whose gene-expression pattern matched long-term event-free survivors. For the data set of Ohira et al. (Fig. 1B) no detailed information about clinical history of investigated patients was available.
Biological roles of the differentially expressed genes
Using the set of 72 significant genes for a hierarchical clustering of MYCN amplified stage 3 or 4 tumours and MYCN non-amplified tumours with stages 1, 2, 4s, both prognosis groups are clearly separated (Fig. 2). Therefore, the expression of these 72 genes seems to be of general importance for distinction of prognosis groups in neuroblastoma tumours.
In the group of genes that shows high expression in tumours with favourable outcome, genes related to cell differentiation (FYN, NTRK1) and neuronal development (DCAMKL1) can be found. Among the significant genes that show a high expression in tumours with unfavourable outcome, cell cycle associated genes can be found (E2F1, CCNA2, CCNB1, KIFC1).
Enriched GO terms in the category "Biological Process" among the significantly differentially expressed genes.
regulation of kinase activity
regulation of protein kinase activity
regulation of transferase activity
negative regulation of transferase activity
negative regulation of protein kinase activity
negative regulation of enzyme activity
regulation of enzyme activity
response to DNA damage stimulus
response to endogenous stimulus
one-carbon compound metabolism
negative regulation of MAPK activity
inactivation of MAPK activity
M phase of mitotic cell cycle
regulation of cyclin dependent protein kinase activity
Wnt receptor signaling pathway
Performance of different markers for outcome prediction on the independent test set.
0.77, [0.66;0.85], (23/30)
0.86, [0.62;0.96], (6/7)
0.74, [0.61;0.84], (17/23)
0.53, [0.42;0.65], (16/30)
1.0, [0.81;1.0], (7/7)
0.39, [0.27;0.52], (9/23)
0.60, [0.48;0.71], (18/30)
1.0, [0.81;1.0], (7/7)
0.48, [0.35;0.61], (11/23)
Age + Stage
0.70, [0.58;0.79], (21/30)
1.0, [0.81;1.0], (7/7)
0.61, [0.48;0.73], (14/23)
In this study, we combined gene expression data from two different studies to investigate the differences in gene expression for advanced stage MYCN non-amplified tumours with contrasting outcome at five years after initial diagnosis.
Our results suggest that this subgroup of tumours can be distinguished into two biological subtypes showing distinct gene expression profiles that are associated with contrasting clinical outcomes. The expression of the genes that are differentially expressed between these two subtypes may represent a general indicator of neuroblastoma aggressiveness, since corresponding expression behaviour can be observed in low stage MYCN non-amplified tumours as well as advanced stage MYCN amplified tumours.
Instead of simply comparing lists of differentially expressed genes obtained on single study data or combining p-values calculated for each single study , we applied a method of meta-analysis on the gene expression data that is based on a well established statistical framework and comprises modelling of study-to-study differences . Unfortunately, the combination of gene expression data from different studies has the disadvantage that only genes common to all microarray platforms can be used. As the reliability of the probe mapping is crucial for a cross-platform analysis, we applied a stringent sequence based mapping of the probes of different microarray platforms in order to avoid inappropriate mapping of the probes. The combination of data from different studies for our analysis resulted in a large number of included expression profiles for the investigated subset of patients although a stringent selection criterion of a follow up of 5 years was applied. This clearly led to a higher statistical power of our analysis in comparison to single study based results, since of the 72 significantly differentially expressed genes, 34 genes were found exclusively in the meta-analysis of both sets.
Among the significantly differentially expressed genes are some that are known in the context of neuroblastoma research. Our results confirm observations made for these genes as described earlier in literature. High expression of NTRK1 is present in neuroblastomas with favourable biological features and highly correlated with patient survival . High expression of FYN and high FYN kinase activity are restricted to low-stage tumours . PTN is highly expressed in favourable neuroblastomas, whereas it is expressed at a significantly lower level in advanced tumours . Low CAMTA1 expression is associated with poor outcome . NCAM expression seems to enhance the malignancy of neuroblastoma cells and their tendency to metastasise . High HuD (ELAVL4) mRNA levels may predict a clinically favourable outcome . The fact that some of these genes were exclusively detected by the meta-analysis (Table 2) underlines the benefit of cross-study analyses for investigation of tumour subgroups. Interestingly, the 72 genes found to be significant for the investigated subgroup of neuroblastoma tumours also show a distinct differential expression in other prognostic subgroups and may thus be used as a general prognostic marker for neuroblastoma patients. Moreover, this result suggests that, although for neuroblastoma tumours several different clinical stages and risk groups are defined, on the level of gene expression they seem to comprise only two distinct biological entities associated with adverse patient outcome.
The GO based gene set enrichment analysis of the GO terms associated with the selected genes in our meta-analysis did not show that any GO term is overrepresented with high statistical significance. However, the p-values calculated in the gene set enrichment analysis provide a useful ranking of the GO annotation terms that we used to select the genes shown in table 3 for characterization of the biological functions represented by the selected genes. Among the GO annotation terms associated with the genes selected in our meta-analysis, the GO-based gene set enrichment analysis highly ranked the cell cycle associated GO terms. The up-regulation of the expression of cell cycle genes in aggressive neuroblastoma tumours was already observed by Krasnoselsky et al.  in a comparison of tumours of different stages and MYCN amplification status, where patient outcome was not regarded. In addition to the cell cycle genes, gene set enrichment analysis of the GO terms associated with the significant genes resulted in high rankings of three other GO terms known to be affected in tumorigenesis: DNA damage response, negative regulation of MAPK activity  and Wnt receptor signalling pathway . For DNA-damage response genes, higher expression can be observed in tumours with a unfavourable outcome than in tumours with favourable outcome. This effect can also be seen in other tumour entities like prostate cancer. For the gene APEX1, gene expression data is available in the gene expression data repository Oncomine  that shows increasing expression according to tumour malignancy (Additional File 1). This effect might be caused by accumulated genetic abberations in tumours with unfavourable outcome which trigger the activity of DNA-damage response genes.
While interpreting the analysis of gene expression for non-amplified advanced stage neuroblastoma tumours with regard to patient outcome, the influence of the therapy that all these patients have received has to be taken into account, as differences of the gene expression profiles with regard to patient outcome may not only reflect tumour malignancy but also tumour responsiveness to the therapy.
Although only a small number of patients were available for generation and assessment of a predictive model, outcome prediction based on data of both studies (only genes common to both platforms) yielded good results. Both patients with favourable and unfavourable outcome were classified with good results as indicated by a balanced ratio of sensitivity and specificity. This shows the potential of the approach to use data of different gene expression studies to derive predictive models for patient subgroups where gene expression data is rare. However, for stable and compact (in terms of the number of used genes) predictive models, a larger total number of samples is needed  which could be realised by combination of future gene expression profiling studies with the approach used here.
In conclusion, cross-study analysis of gene expression data enables to detect consistent effects of gene expression based on completely independent data sets. The increase of statistical power through cross-study analysis is especially beneficial for the analysis of important patient subgroups for which gene expression data is rare. The presented results characterise a patient outcome specific set of differentially expressed genes in MYCN non-amplified advanced stage tumours. The resemblance of the expression of these genes in the investigated subgroup and in tumours with clearly defined (and diverging) outcome suggests that neuroblastomas comprise only two distinct biological subtypes associated with contrasting patient outcome.
Further investigations are needed to extend and validate these findings, a process in which the combination of future gene expression profiling studies which are larger both with respect to the investigated patients and probes on the utilised microarray platforms (thus yielding a large intersection of common probes), could play an important role.
We thank Miki Ohira, Ph.D. and Akira Nakagawara, M.D., Ph.D. for provision of additional clinical data. PW receives a grant from the DFG Graduiertenkolleg 886. The authors acknowledge financial support by the National Genome Research Network (01 GR 0450, 01 GS 0457), by the Deutsche Krebshilfe (FKZ 50-2719-Fi-1), and by the European Union's 6th Framework Programme (LSHC-CT-2005-018911).
- Schwab M, Westermann F, Hero B, Berthold F: Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 2003, 4: 472-480. 10.1016/S1470-2045(03)01166-5.View ArticlePubMedGoogle Scholar
- Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003, 3: 203-216. 10.1038/nrc1014.View ArticlePubMedGoogle Scholar
- Cheung NK, Cohn S: Neuroblastoma. 2005, Berlin: SpringerView ArticleGoogle Scholar
- Maris JM: The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005, 17: 7-13. 10.1097/01.mop.0000150631.60571.89.View ArticlePubMedGoogle Scholar
- Wei JS, Greer BT, Westermann F, Steinberg SM, Son C, Chen Q, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, Catchpoole D, Berthold F, Schwab M, Khan J: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 2004, 64: 6883-6891. 10.1158/0008-5472.CAN-04-0695.View ArticlePubMedPubMed CentralGoogle Scholar
- Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, Christiansen H, Warnat P, Brors B, Eils J, Eils R, Eggert A: Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene. 2005, 24: 7902-7912. 10.1038/sj.onc.1208936.View ArticlePubMedGoogle Scholar
- Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, Hirata T, Kubo H, Goto T, Yamada S, Yoshida Y, Fuchioka M, Ishii S, Nakagawara A: Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell. 2005, 7: 337-50. 10.1016/j.ccr.2005.03.019.View ArticlePubMedGoogle Scholar
- Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M: Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. Journal of Clinical Oncology. 2006, 24: 5070-8. 10.1200/JCO.2006.06.1879.View ArticlePubMedGoogle Scholar
- Ransohoff DF: Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer. 2004, 4: 309-314. 10.1038/nrc1322.View ArticlePubMedGoogle Scholar
- Choi JK, Yu U, Kim S, Yoo OJ: Combining multiple microarray studies and modeling interstudy variation. Bioinformatics. 2003, 19 (Suppl 1): i84-i90. 10.1093/bioinformatics/btg1010.View ArticlePubMedGoogle Scholar
- Warnat P, Eils R, Brors B: Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. BMC Bioinformatics. 2005, 6: 265-10.1186/1471-2105-6-265.View ArticlePubMedPubMed CentralGoogle Scholar
- Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J: Independence and reproducibility across microarray platforms. Nat Methods. 2005, 2: 337-344. 10.1038/nmeth757.View ArticlePubMedGoogle Scholar
- Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau W, Ledoux P, Rudnev D, Lash AE, Fujibuchi W, Edgar R: NCBI GEO: mining millions of expression profiles-database and tools. Nucleic Acids Res. 2005, D562-6. 33 DatabaseGoogle Scholar
- Parkinson H, Sarkans U, Shojatalab M, Abeygunawardena N, Contrino S, Coulson R, Farne A, Lara GG, Holloway E, Kapushesky M, Lilja P, Mukherjee G, Oezcimen A, Rayner T, Rocca-Serra P, Sharma A, Sansone S, Brazma A: ArrayExpress-a public repository for microarray gene expression data at the EBI. Nucleic Acids Res. 2005, D553-D555. 33 DatabaseGoogle Scholar
- Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JYH, Zhang J: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5: R80-10.1186/gb-2004-5-10-r80.View ArticlePubMedPubMed CentralGoogle Scholar
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000, 25: 25-29. 10.1038/75556.View ArticlePubMedPubMed CentralGoogle Scholar
- Beissbarth T, Speed TP: GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics. 2004, 20: 1464-1465. 10.1093/bioinformatics/bth088.View ArticlePubMedGoogle Scholar
- Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA. 2002, 99: 6567-6572. 10.1073/pnas.082099299.View ArticlePubMedPubMed CentralGoogle Scholar
- Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM: Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002, 62: 4427-4433.PubMedGoogle Scholar
- Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993, 328: 847-854. 10.1056/NEJM199303253281205.View ArticlePubMedGoogle Scholar
- Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M, Kartal A, Flynn D, Wiedemeyer R, Schwab M, Schäfer H, Christiansen H, Eilers M: Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell. 2002, 2: 377-386. 10.1016/S1535-6108(02)00179-4.View ArticlePubMedGoogle Scholar
- Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, Brodeur GM: Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res. 1995, 55: 1792-1797.PubMedGoogle Scholar
- Henrich K, Fischer M, Mertens D, Benner A, Wiedemeyer R, Brors B, Oberthuer A, Berthold F, Wei JS, Khan J, Schwab M, Westermann F: Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin Cancer Res. 2006, 12: 131-138. 10.1158/1078-0432.CCR-05-1431.View ArticlePubMedGoogle Scholar
- Gluer S, Zense M, Radtke E, von Schweinitz D: Expression of polysialylated NCAM on neuroblastomas of various histology and clinical stages. Langenbecks Arch Chir Suppl Kongressbd. 1998, 115 (Suppl I): 289-292.PubMedGoogle Scholar
- Ball NS, King PH: Neuron-specific hel-N1 and HuD as novel molecular markers of neuroblastoma: a correlation of HuD messenger RNA levels with favorable prognostic features. Clin Cancer Res. 1997, 3: 1859-1865.PubMedGoogle Scholar
- Krasnoselsky AL, Whiteford CC, Wei JS, Bilke S, Westermann F, Chen Q, Khan J: Altered expression of cell cycle genes distinguishes aggressive neuroblastoma. Oncogene. 2005, 24: 1533-1541. 10.1038/sj.onc.1208341.View ArticlePubMedGoogle Scholar
- Freeman SM, Whartenby KA: The role of the mitogen-activated protein kinase cellular signaling pathway in tumor cell survival and apoptosis. Drug News Perspect. 2004, 17: 237-242. 10.1358/dnp.2004.17.4.829050.View ArticlePubMedGoogle Scholar
- Karim R, Tse G, Putti T, Scolyer R, Lee S: The significance of the Wnt pathway in the pathology of human cancers. Pathology. 2004, 36: 120-128. 10.1080/00313020410001671957.View ArticlePubMedGoogle Scholar
- Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM: ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004, 6: 1-6.View ArticlePubMedPubMed CentralGoogle Scholar
- Ein-Dor L, Zuk O, Domany E: Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA. 2006, 103: 5923-8. 10.1073/pnas.0601231103.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/7/89/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.